LENZ Therapeutics, Inc. LENZ Open LENZ Therapeutics, Inc. in new tab
LENZ Therapeutics, Inc. Analysis (LENZ)
Is LENZ Therapeutics, Inc. a good investment? LENZ Therapeutics, Inc. (LENZ) is currently trading at 6.90 USD. Market analysts have a consensus price target of 34.57 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 45.73. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: LENZ Therapeutics, Inc. is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is -3.25.
Investor FAQ
Does LENZ Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of -3.64.
Company Profile
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2024 | 14.42 USD |
| March 22, 2024 | 7.2100 |
| March 15, 2024 | 7.2100 |
Yearly aggregated dividends
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| March 22, 2024 | 0.140000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion